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Abstract
Identification of HLA-restricted CD8
+ T cell epitopes is important to study RSV-induced immunity and illness. We
algorithmically analyzed the sequence of the fusion protein (F) of respiratory syncytial virus (RSV) and generated synthetic
peptides that can potentially bind to HLA-A*0201. Four out of the twenty-five 9-mer peptides tested: peptides 3 (F33–41),
13 (F214–222), 14 (F273–281), and 23 (F559–567), were found to bind to HLA-A*0201 with moderate to high affinity and
were capable of inducing IFN-c and IL-2 secretion in lymphocytes from HLA-A*0201 transgenic (HLA-Tg) mice pre-
immunized with RSV or recombinant adenovirus expressing RSV F. HLA-Tg mice were immunized with these four peptides
and were found to induce both Th1 and CD8
+ T cell responses in in vitro secondary recall. Effector responses induced by
these peptides were observed to confer differential protection against live RSV challenge. These peptides also caused better
recovery of body weight loss induced by RSV. A significant reduction of lung viral load was observed in mice immunized
with peptide 23, which appeared to enhance the levels of inflammatory chemokines (CCL17, CCL22, and IL-18) but did not
increase eosinophil infiltration in the lungs. Whereas, significant reduction of infiltrated eosinophils induced by RSV
infection was found in mice pre-immunized with peptide 13. Our results suggest that HLA-A2-restricted epitopes of RSV F
protein could be useful for the development of epitope-based RSV vaccine.
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Introduction
Respiratory syncytial virus (RSV) induces respiratory disease in
children and the elderly around the globe [1,2,3], and till now,
there is no effective prophylactic vaccine available against RSV
infection. Previous attempts in developing a vaccine using
formalin-inactivated RSV failed because it exacerbated the disease
upon subsequent infection in some cases [4]. Therefore, study and
development of a vaccine against RSV is a priority to global
welfare. Many studies conducted in animal models have
convincingly shown that not only neutralizing antibodies but also
CD8
+ cytotoxic T lymphocytes (CTLs) confer protection against
viral infections. The role of CTLs seems to be dual in RSV
infection. Adoptive transfer of CD8
+ CTLs offers protection to
recipient BALB/c mice from subsequent infection by limiting viral
replication in vivo [5], and also inhibits RSV vaccine induced
pulmonary eosinophilia [6]. This function is dependent on the
numbers of CD8
+ CTLs in the lungs to inhibit pulmonary
eosinophilia as well as the production of type 2 helper T cell (Th2)
associated chemokines in mice [7]. On the other hand, excess
CD8
+ CTLs contributed to RSV-induced lung pathogenesis in
mice [5,8]; they were detected more readily in human adults who
develop mild symptoms following virus exposure [9], but not so
clear in infants [6]. In addition to CD8
+ T cells, studies of RSV
infection reveal that CD4
+ T cell concurrence leads to IL-2
secretion, restores CTL activation in RSV-infected respiratory
tract [10] and increases CD8
+ T cell activation via IFN-c
production after in vitro peptide stimulation [11]. In contrast, IL-
4 secreted from CD4
+ T cells can abrogate CD8
+ T cell response
and diminish viral clearance [12,13].
While T cell responses are required to clear RSV from the
lungs, studies in murine model show that CD8
+ T cell response
against the fusion protein (F) regulates the outcome of CD4
+ T cell
responses in preventing vaccine-enhanced disease [14]. RSV
challenge of BALB/c mice previously immunized with vaccinia
virus (vacv) expressing RSV F protein does not lead to the
development of pulmonary eosinophilia [14,15,16,17]. CD8
+ T
cells recognize 8–10 amino acids long peptide epitopes in the
context of MHC class I and upon activation, mount a specific
cytotoxic response against virus-infected cells. In humans, a
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in the nucleocapsid (N) protein, F protein, M2-1 protein (encoded
by the first of two open reading frames (ORFs) of the matrix
protein (M2) gene), and the short hydrophobic (SH) protein
[18,19,20,21,22]. In mice, epitopes specific for CD8
+ T cells have
been identified in F, G, matrix (M) and M2-1 proteins
[23,24,25,26,27]. F protein elicits CTL responses in humans
[19] and mice [24,28] and enhances the production of Th1
cytokines, IL-2, IL-12 and IFN-c. Therefore, identification of
CD8
+ T cell epitopes derived from F protein that are restricted to
human HLA is important for the development of RSV vaccine.
The classical techniques used to enumerate CTL responses and
epitope identification in humans has many limitations such as
small blood sample volume that can be obtained safely from
acutely infected young patients, the low frequency of RSV-specific
memory CTL response in adults who were not recently infected
[29], and the diversity of HLA class I gene polymorphism in
donors. HLA-transgenic mice have been recognized as model to
identity and study of epitope-specific CTL responses against
viruses [30,31,32,33,34,35]. In our study, we have predicted
human HLA-A*0201-restricted CD8 epitopes from RSV F protein
using the computational program named HLA Peptide Binding
Predictions. These peptide epitopes have 9-mer amino acid core
sequences and their association with the MHC class I molecule
HLA-A*0201 was confirmed. These epitopes could also stimulate
splenocytes from HLA-A*0201 transgenic (HLA-Tg) mice immu-
nized with either RSV or recombinant adenovirus carrying F gene
(rAd-F0) leading to enhanced production of IFN-c and IL-2. In
our system, peptide 13 (F214–222), peptide 14 (F273–281), and
peptide 23 (F559–567) were found to be immunodominant,
conferring viral clearance, and protection from RSV-induced
body weight loss and lung pathology, with peptide 23 offering
maximum protection. Collectively, the novel HLA-A*0201-
restricted epitopes described here that elicit protective anti-viral
responses are forerunners in the study of peptide-based RSV
vaccine.
Materials and Methods
Ethics statement
All experiments were conducted in accordance with the
guidelines of the Laboratory Animal Center of National Health
Research Institutes (NHRI), Taiwan. The animal use protocols
have been reviewed and approved by the NHRI Institutional
Animal Care and Use Committee (Approved protocol no. NHRI-
IACUC-098078-A).
Animals and Cell lines
Eight to ten week-old female human HLA-A*0201 transgenic
C57BL/6 mice, expressing cell surface HLA-A*0201, were gifted
by Dr. Shih-Jen Liu, Institute of Infectious Disease and
Vaccinology, NHRI, Taiwan, and C57BL/6 (H-2K
b) and
BALB/c (H-2K
d) mice were purchased from National Laboratory
Animal Center, Taiwan. The mice were maintained in pathogen-
free conditions at the Animal Care Center of National Health
Research Institutes throughout the period of study. Human T2
cells (purchased from the American Type Culture Collection,
ATCC) (ATCC No. CRL-1992) expressing the HLA-A*0201
gene, but unable to present endogenous antigen, were cultured in
IMDM (Hyclone)+10% fetal bovine serum (Biological Industries).
Human embryonic kidney cells (293A) were purchased from
Invitrogen (Cat. No. R70507). Human larynx carcinoma cells
(HEp-2) were kindly obtained from Dr. Barney S. Graham,
Vaccine Research Center, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Bethesda, USA.
The original HEp-2 cells were purchased from ATCC (ATCC
No. CCL-23). 293A and HEp-2 were grown and maintained in
DMEM medium (Hyclone) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin (P/S) (Biological Indus-
tries). All the cell lines were grown in an incubator maintained at
37uC and equilibrated with 5% CO2.
Selection and synthesis of HLA-A*0201-restricted
peptides
Twenty-five HLA-A*0201- restricted 9-mer- peptide sequences
(Table 1) were derived from the F protein of RSV-B1 strain using the
computational program of HLA Peptide Binding Predictions
developed by Bioinformatics and Molecular Analysis Section,
National Institutes of Health (http://www-bimas.cit.nih.gov/molbio/
hla_bind/). Epstein-Barr virus peptide, GLC-9 (GLCTLVAML)
[36], known to be capable of binding to HLA-A*0201, was used as
the positive control in T2 cell-stabilization assay. Hepatitis C virus
capsid protein peptide ‘‘RPQPRGRRQPIPKARQPEGR’’ (HCV
C55-74), which is a specific CD4 epitope for C57BL/6 mice, was
used as the negative control. All the peptides were commercially
synthesized by Echo Chemic, Ltd. and had 95% purity as confirmed
by high-performance liquid chromatography. These peptides were
dissolved in DMSO and diluted in the culture medium.
T2 cell-stabilization assay
T2 cells (5610
5) cultured in 96-well U-bottom plates were
incubated with the individual 9-mer synthetic peptides (50 mg/mL)
and b2-microglobulin (5 mg/mL; Sigma-Aldrich) at 28uC for 16–
18 hours. Subsequently, brefeldin A (10 mg/mL) was added and
the cells were incubated at 37uC for another 3 hours, then washed
and stained with fluorescence isothiocyanate (FITC)-conjugated
mouse anti-human HLA-A2 antibody (SeroTec). Peptide-loaded
T2 cells were acquired and analyzed on the FACScan flow
cytometer using CellQuest software (Becton Dickinson). GLC-9
peptide was used as positive control (PC). The mean fluorescence
intensity (MFI) represents the binding affinity of each peptide
compared to MFI (set as MFI=1) obtained from negative control
(NC), which is T2 cells loaded with HCV peptide C55-74.
Preparation of RSV-B1 strain stocks and rAd-F0
The propagation of human RSV-B1 strain VR-1580 (purchased
from the American Type Culture Collection) in HEp-2 cells was
described previously [37]. The virus was collected and resus-
pended in PBS, pH 7.2 and the titer was determined by a standard
plaque assay. Briefly, 100 mL of varying dilutions of purified virus
preparations was added to 5610
5 HEp-2 cells in a 12-well plate
(Corning). Each culture was then overlaid with DMEM containing
1.5% methylcellulose (Sigma-Aldrich) and incubated for 5 to 6
days for the plaques to develop. Plaques stained with hematoxylin
and eosin (H/E) were counted under a light microscope. The viral
concentration is expressed as plaque-forming units per mL (pfu/
mL). Propagation of rAd-F0 has been described previously [37].
Purification and concentration of the rAd-F0 was achieved by
ultracentrifugation through a 15% sucrose/PBS gradient at
20,000 rpm for 60 min.
The virus was then resuspended in PBS, pH 7.2, and the titer
determined by the modified plaque assay described above. Briefly,
varying dilutions of rAd-F0 virus was added to 293A cells plated in
a 12-well tissue culture plate. After overlaying the cultures with
DMEM containing 0.75% methylcellulose, the cultures were
incubated at 37uC for 10 to 12 days and plaques stained with H/E
were counted. The yield of rAd-F0 was ,1610
9 pfu/mL.
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To screen the immunodominance of epitopic peptide in the
induction of RSV-F specific Th1/Th2 expression, HLA-A*0201
transgenic C57BL/6 mice were anesthetized with isoflurane and
immunized with 1610
7 pfu/50 mL of rAd-F0 or rAd-LacZ or
1610
4 live RSV B1 via the intranasal (i.n.) route. Twenty days
later, the mice were given booster immunization i.n. with the same
dose. After 10 days of boost, mice were sacrificed and splenocytes
were isolated for the cytokine ELISPOT assay. For peptide-based
vaccination, transgenic mice were immunized subcutaneously (s.c.)
with 50 mg of the individual synthetic peptides emulsified in 25 mL
of incomplete Freund’s adjuvant (IFA) (Sigma-Aldrich) and then
boosted after 10 days s.c. with the same dose of the respective
peptides mixed with IFA. Mice were sacrificed 7 days after the
booster and splenocytes were isolated for in vitro peptide-
restimulation. For challenge studies, 10
7 pfu of live RSV-B1 was
administered i.n. seven days after the booster immunization with
peptide vaccines. Mice were sacrificed on day 4 post-challenge and
the lung tissues were collected and subjected to further analysis by
flow cytometry, ELISA, CTL assay and immunohistochemistry.
Mice body weight was monitored daily.
Enzyme-linked immunosorbent spot (ELISPOT) assay
5610
6 RBC-free splenocyte suspensions prepared from the
individual mice were seeded in individual wells of 96-well filtration
plates (Millipore) precoated with capturing monoclonal antibodies
for murine IL-2, IL-4 or IFN-c (0.5 mg/ well) (eBioscience) and
blocked with conditioned medium (CM) for 1 hour at room
temperature. The splenocytes were added with the individual RSV
F 9-mer synthetic peptides (2 mg each) or GLC-9 dissolved in CM
(100 mL). The splenocytes added with Con A (10 mg/mL) were
used as positive control. Unstimulated splenocytes were used as
negative control. The plates were kept in a 37uC incubator
equilibrated with 5% CO2 for 48 hours. The individual wells of
the ELISPOT plates were washed three times with washing buffer
(0.05% tween20 in PBS, PBS-T), and then 0.2 mg of the
corresponding biotinylated detection monoclonal antibodies
specific for IL-2, IL-4 and IFN-c were added to detect the
Table 1. Characteristics of HLA-A*0201-restricted epitopes of peptide spanning RSV F protein*.
No. Sequence T2-binding Ratio of MFI IFN-c ELISPOT IL-2 ELISPOT
rAd-F0 RSV rAd-F0 RSV
N RPQPRGRRQPIPKARQPEGRL 1.00 N/a** N/a N/a N/a
EBV GLCTLVAML 1.96 N/a N/a N/a N/a
1 TLLLWVLLL 1.19 33.5 69.5 85.5 39.5
2 LLWVLLLWV 0.97 46.5 46.5 34.5 42
3 AITTILAAV 1.71 68.5 119.5 9 31
4 ELDKYKNAV 0.94 88.5 34.5 49.5 51.5
5 FMNYTLNNT 0.96 73 12.5 38 58.5
6 FLLGVGSAI 1.14 65 61.5 29 32
7 HLEGEVNKI 0.83 68.5 81 68 33
8 ALLSTNKAV 1.50 36 86 8.5 43
9 LLSTNKAVV 1.53 27.5 1 5 2
10 STNKAVVSL 0.91 43 9.5 0 39.5
11 SLSNGVSVL 1.06 68.5 200 51.5 56.5
12 VLTSKVLDL 0.99 95.5 116.5 44 36
13 KVLDLKNYI 1.26 200 103.5 85 35.5
14 YMLTNSELL 1.71 200 97 200 34.5
15 KLMSNNVQI 1.51 39 0 37 59.5
16 LMSNNVQIV 1.60 54 28 52 50.5
17 KIMTSKTDV 0.95 24.5 2.5 24.5 6.5
18 SVGNTLYYV 1.29 115 92.5 0 42
19 KINQSLAFI 1.08 200 7.5 52 36.5
20 IMITTIIIV 1.03 200 9 32 24.5
21 IIIVIIVIL 0.88 16.5 80 2.5 21
22 VIIVILLSL 0.97 88.5 49 21.5 55
23 VILLSLIAV 1.51 130.5 87.5 34.5 43.5
24 LLSLIAVGL 1.71 84.5 0 5 42
25 SLIAVGLLL 1.42 41 96 31 44.5
*Twenty-five HLA-A*0201-restricted 9-mer synthetic peptides from F protein of RSV-B1 strain were tested their binding ability with HLA-A*0201 by T2-stabilization assay,
which has been described in the Materials and Methods. The study is a representative of results derived from two independent experiments, each with five mice per
group. Results of IFN-c and IL-2 ELISPOT assays have been described in the legend of figure 1.
**N/a, not assayed.
doi:10.1371/journal.pone.0025500.t001
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temperature, the plates were washed and 100 ml of streptavidin-
alkaline phosphatase (1: 250 dilution) was added to the individual
wells, and the plates were incubated at room temperature for
45 minutes. Finally, the plates were washed four times with the
wash buffer, and 100 ml of AEC (3-amine-9-ethylcarbazole,
Sigma-Aldrich) substrate was added to each well and allowed to
react for 30 minutes at room temperature in the dark. The plates
were then washed with water, air-dried overnight, and the spots
per well were scored using the immunospot counting reader
(C.T.L. IMMUNOSPOT, CELLULAR TECHNOLOGY LTD).
Results were expressed as the number of cytokine-secreting cells
per 5610
5 splenocytes seeded in the initial culture.
In vitro peptide restimulation for T cell activation
The splenocytes were isolated, labeled with 5-(6)-carboxyfluor-
escein diacetate succinimidyl ester (CFSE) (Sigma-Aldrich) and
stimulated in vitro with 10 mg/mL of the synthetic peptides for 4 or
8 days. Proliferation of splenocytic CD4
+ and CD8
+ T cells was
analyzed by flow cytometry (BD FACSCalibur) using PE-Cy5-
labeled specific antibody against CD4 (eBioscience) or CD8
(eBioscience), respectively. Cell division index (CDI), a ratio of
CFSE-diluted CD4
+ or CD8
+ T cells stimulated by peptide to
CFSE-diluted unstimulated CD4
+ or CD8
+ T cells, was calculated
as shown below;
CDI for CD4z T cells
~
In vitro peptide-restimulated CD4zCFSE low=CFSE high
No-restimulated CD4zCFSE low=CFSE high
|100%,
CDI for CD8z T cells
~
In vitro peptide-restimulated CD8zCFSE low=CFSE high
No-restimulated CD8zCFSE low=CFSE high
|100%
CDI represents the lymphocyte proliferation in response to
individual peptide epitope stimulation.
For IFN-c intracellular staining, splenocytes from peptide- or
vehicle-immunized mice were stimulated in vitro with the respective
peptides (peptide 3, 13, 14, and 23) (10 mg/mL) for five hours,
washed with 16 PBS, and stained with anti-CD8 antibody
conjugated with fluorescein isothiocyanate (FITC) (BD Bioscienc-
es) for 30 minutes, followed by subsequent fixation and permea-
bilization following the instructions of eBioscience fixation and
permeabilization kit. The splenocytes were further stained for
intracellular IFN-c using PE-conjugated anti-IFN-c antibody (BD
Biosciences) for another 30 minutes. After washing, the samples
were analyzed using flow cytometry.
Preparation of lung homogenate
Whole lungs were perfused with 5 mL 16PBS before excision.
The isolated lung tissues were incubated with 1 mg/mL collage-
nase for 30 min before homogenizing with the iron mesh. The
homogenate was centrifuged at 1,000 rpm for 10 min at 4uCt o
sediment the pulmonary cells. The cells were washed with 16PBS
and then resuspended in 16PBS for further analysis by real-time
RT-PCR and flow cytometry. For pulmonary IFN-c detection,
5610
6/mL cells were cultured with 10 U/mL recombinant IL-2
for 2 days and the supernatants were collected for ELISA.
Viral load determination
The PBS-perfused homogenized tissues were centrifuged at
1,000 rpm for 10 min at 4uC to sediment cell debris. Supernatants
were collected, serially diluted, and tested for their ability to infect
HEp-2 cells in the plaque formation assay as described above.
Real-time RT-PCR
Lung RNA (5 mg) was mixed with 10 nmole random primers
and 2 units of MMTV reverse transcriptase (Invitrogen) and
incubated at 94uC for 10 minutes, 37uC for 30 minutes, and then
at 4uC. The resulting cDNA was subjected to quantitative PCR
analysis (The LightCyclerH 480 Real-Time PCR system) with
RSV N specific primer pairs, forward: 59-aagatgcaaatcataaattca-
cagga-39 and reverse: 59-tgatatccagcatctttaagtatctttatagtg-39.
Expression of mouse GAPDH gene in the tested samples
was detected as internal control by using specific primer
pairs, forward: 59-acccagaagactgtggatgg-39 and reverse: 59-
acacattgggggtaggaaca-39. The number of cycles (Ct) required
for the amplification of the N gene and GAPDH was calculated.
The relative expression of the N gene was calculated as followed:
the individual Ct (RSV N) obtained from peptide- or vehicle-
immunized lung was normalized by the respective Ct (GAPDH),
and then 2Normalized Ct peptide-immuninzed cDNA ðÞ was divided by the
mean of 2Normalized Ct vehicle-immuninzed cDNA ðÞ . For detection of
expression of chemokine genes in the lungs, primer pairs specific
to CCL11, forward: 59-tccacagcgcttctattcct-39 and reverse: 59-
ctatggctttcagggtgcat-39, to CCL17, forward: 59-agtggagtgttccagg-
gatg-39 and reverse: 59-ctggtcacaggccgttttat-39, and to CCL22,
forward: 59-aaatgctcgccaatgatacc-39 and reverse: 59-aaggaagccac-
caatgacac-39 were used. To measure pulmonary cytokine
expression in mice, primer pairs specific to IL-13, forward: 59-
cagctccctggttctctcac-39 and reverse: 59-ccacactccataccatgctg-39,t o
IL-17a, forward: 59-gattttcagcaaggaatgtgg-39 and reverse: 59-
cattgtggagggcagacaat-39, and to IL-18, forward: 59-acgtgttccag-
gacacaaca-39 and reverse: 59-acaaaccctccccacctaac-39 were used.
The relative expression of the chemokine gene was calculated as
the same as RSV N gene described above. All primer sets were
synthesized commercially by Echo Chemic, Ltd, Taiwan.
ELISA
The supernatants from 2-day culture of pulmonary cells were
analyzed by calorimetric sandwich IFN-c ELISA kit (eBioscience).
Briefly, 96-well plates were coated with100 mL per well of anti-
IFN-c capturing monoclonal antibodies (1:1000) in carbonate-
coated buffer. The plates were incubated at 4uC overnight
following by incubation with 16 assay diluent for one hour at
room temperature. After three washings with PBS-T, biotinylated
anti-mouse IFN-c antibody (1:1000) was added into each well for
30 minutes. The plate was washed with PBS-T and 100 mLo f
avidin conjugated with horseradish peroxidase (1:250) was added
to the individual wells for 30 minutes. The reaction was developed
by 100 mL TMB substrate (3, 39,5 ,5 9-etramethyllbenzidine) for
20 minutes incubation in a dark room, and then terminated by
adding 50 mLo f2NH 2SO4. The optical densities at 450 nm
were determined with a microplate absorbance reader (SPEC-
TRA, MAX2, M2).
Isolation and culture of dendritic cells
Dendritic cells (DCs) isolated from HLA-A*0201-Tg B6 mice
were used as target cells for CTL assay. Briefly, tibia were isolated
from 6–8 weeks old mice and rinsed with 75% alcohol before their
incubation with lymphocyte culture medium (LCM, RPMI
containing 5% FBS, 20 mM HEPES, 50 mM 2-mecaptoenthanol,
Novel HLA-A2 CTL Epitopes in RSV F Protein
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e2550016 P/S). The myeloid tissues were removed from the tibia with
LCM and filtrated through 40 mm cell strainer (BD Falcon). The
filtrates were centrifuged at 1200 rpm for 5 minutes and the cell
pellet was resuspended in 2 mL RBC lysis solution (eBioscience),
and incubated for 5 minutes followed by addition of 10 mL of 16
PBS buffer to stop lysis. Cells were centrifuged, washed once with
16 PBS, and resuspended in LCM containing 100 U/ml GM-
CSF and cultured in an incubator maintained at 37uC,
equilibrated with 5% CO2 for 6 days. At day 6, 10 mg/mL
peptide epitopes and 5 mg/mL b2-microglobulin were added to
the DC culture and incubated for another 24 hours. The peptide-
pulsed DCs (10
6) were treated with 50 ng/mL lipopolysaccharide
(LPS) for one hour, labeled with CFSE in 1 mL of 16 CFSE
staining solution, incubated at room temperature for 15 minutes,
and then centrifuged at 4006 g for 5 minutes to remove the
supernatant, and were used as target cells in CTL assay.
CTL assay
A non-radioactive assay for cell-mediated cytotoxicity using a
green fluorescent probe CFSE to label target cells in combination
with 7-amino-actinomycin D (7AAD), a red fluorescent probe to
label dead effectors and target cells [38], was used to assess the
presence of RSV F protein-specific CTLs in spleens or lungs of the
immunized animals. The assay was carried out in accordance with
the manufacturer’s instructions (Cayman Chemical, Michigan,
USA. catalog No. 600120). The assay entailed culturing spleno-
cytes (5610
6) with a tested synthetic peptide (5 mg/mL) known to
be a dominant HLA-A*0201-restricted CTL epitope in the
presence of recombinant IL-2 (10 U/mL) at 37uC for 4 days.
Peptide-loaded CFSE-labeled DCs isolated from HLA-Tg B6 mice
were used as target cells. Un-pulsed DCs labeled with CFSE
served as negative control. The target cells were resuspended in
the culture medium and incubated at 37uCi naC O 2 incubator for
30 minutes and then plated onto 12-well plates (10
4/well, 250 mL)
and co-cultivated with an appropriate number of in vitro
restimulated splenocytes (as effectors) in defined effector:target
(E:T) ratios in triplicates. Four hours later, the cell mixture was
centrifuged and the pellet was resuspended in the 7AAD staining
solution (1 mL), and kept in the dark for 15 minutes at 4uC. The
cells were re-centrifuged again and the pellet was resuspended in
1 mL of assay buffer for analysis by flow cytometry. CFSE was
measured in FL1 channel and 7-AAD in FL3 channel. The
percentage of CFSE/7-AAD double positive target cells (i.e., DCs
cell death) was analyzed. Target cells without CFSE or 7-AAD
staining or only with CFSE staining were used as internal controls.
Immunohistochemistry
Whole lungs were excised from the mice, fixed in 10% formalin
(Sigma-Aldrich) solution overnight and embedded in paraffin
(Thermo Fisher Scientific) for sectioning. The sections were
stained with rat monoclonal anti-major basic protein (MBP)
antibody (1:500 dilution, gifted from Dr. James J. Lee, Mayo
Clinic, AZ, USA) followed by the appropriate secondary
antibodies. Twenty-bright field microscopy pictures (Nikon
DXM1200 CCD digital camera attached with ACT-1 imaging
capture software) from each stained section were taken at 2006
magnifications and the number of eosinophils was counted. The
mean of eosinophil count from each section was calculated.
Statistical analysis
Unpaired, two-tailed student t test was used to compare the
results obtained from the different experimental groups. Results
are considered statistically significant when the p value is ,0.05.
The symbols * and ** are used to indicate p values,0.05 and
,0.01, respectively.
Results
Screening of synthetic peptides for HLA-A2 binding and
T lymphocyte activation
Twenty-five 9-mer synthetic peptides derived from the RSV F
glycoprotein sequence presumed to encompass HLA-A*0201
binding motifs were synthesized (Table 1). Each was tested for
its ability to bind HLA-A*0201 molecules by T2 cell-based
binding assay (data not shown). The relative mean fluorescence
intensity (MFI) obtained from the positive control (PC) peptide
derived from Epstein-Barr virus capsid protein (GLC-9, a
previously defined HLA-A*0201-restricted CTL epitope) was
twofold (MFI=1.96) compared to the baseline MFI=1 obtained
from the negative control (NC) treated with an unrelated peptide
HCV C55-74 (a C57BL/6-specific CD4 epitope). The peptides 3,
9, 14, 15, 16, 23, and 24 showed 1.5 fold greater MFI than the
negative control. The peptides 1, 6, 8, 13, 18, and 25 showed only
modest binding affinity (,10% higher than the baseline). The
remaining peptides had no detectable binding to the HLA-A*0201
molecules. Apparently, the different MFIs generated by binding of
RSV F-derived peptides to HLA-A*0201 reflects on the binding
specificity of different peptides to a given HLA molecule.
To screen these peptides for their ability to activate RSV F-
specific T cells, HLA-A*0201 transgenic C57BL/6 mice (HLA-Tg
B6) were primed and boosted with rAd-F0- or RSV B1,
splenocytes were harvested 10 days after the boost and then
restimulated in vitro with the individual RSV F peptides. The
peptide HCV C55-74 was not included because it had no binding
to HLA-A*0201 molecules. The production of IFN-c and IL-2
was measured by ELISPOT assay. Expression of HLA-A*0201 in
the splenocytes isolated from HLA-Tg B6 mice was confirmed by
flow cytometry using FITC-conjugated HLA-A*0201-specific
antibody (data not shown). The peptides 3, 11, 12, 13, 14, 18,
19, 20, and 23 induced high levels of IFN-c (over 100 spots) in the
restimulated splenocytes. On the other hand, the peptides 1, 2, 4,
5, 6, 7, 8, 16, 21, 22, 24, and 25 only elicited moderate IFN-c
secretion (over 50 spots) (fig. 1A). Peptide 14 induced high
production of IL-2 (over 100 spots), while the peptides, 1, 4, 5, 7,
11, 13, 15, 16, 19, and 22 induced moderate levels of IL-2 (over 50
spots) (fig. 1B). IL-4 production was minimal in all the samples
(data not shown) indicating that Th1 rather than Th2 immune
response was activated. Ultimately, among these CD8 epitope
candidates, the critical factors to determine a suitable peptide are
strong binding to HLA-A*0201 (ratio of MFI .1.2) and IFN-c
cytokine production (over 60 spots in both RSV and rAd-F0
immunization). Based on these criteria, the peptides 3 (F33–41), 13
(F214–222), 14 (F273–281), and 23 (F559–567) (Table 1) were
chosen for further examination of the efficacy of peptide-based
vaccination in HLA-Tg B6 mice.
Evaluation of immunogenicity of the peptide epitopes in
HLA-A*0201 transgenic B6 mice
To test the immunogenicity of the selected peptides, HLA-Tg
B6 mice were immunized twice with the individual IFA-emulsified
peptides 3, 13, 14, 17, or 23, at day 0 and day 10. Seven days post
boosting, the splenocytes were harvested, labeled with CFSE, and
restimulated with the respective peptides. In these experiments,
peptide 17 with only a background binding to HLA-A*0201 and
lower induction of Th1 cytokines (Table 1) was included as a
control. Proliferation of CD4
+ and CD8
+ lymphocytes in response
to peptide stimulation was analyzed by flow cytometry and the cell
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and Methods. Neither CD4
+ nor CD8
+ lymphocyte proliferation
was detected 4 days after restimulation (data not shown). After 8
days of stimulation, it was observed that the peptides 3, 14, 17, and
23 induced insignificant proliferation of CD4
+ T cells (Fig. 2A)
while the proliferation of CD8
+ T cells was ,2-fold in response to
peptide 3, ,3-fold in response to peptide14, and ,1.5-fold in
response to peptide 23 (Fig. 2B). Based on these observations,
peptide 17, which could not induce proliferation of CD8
+ T cells,
showed poor binding to HLA-A*0201 and lower induction of Th1
cytokines and was excluded from further investigations.
It has been reported that in BALB/c mice infected with RSV,
activated IFN-c
+/CD8
+ T cells generated against the viral
proteins, F, matrix 2 (M2) and N played a protective role in viral
clearance [23,28,39,40]. We found that immunization with the
peptides 14 and 23 marginally increased the proportion of IFN-
c
+/CD8
+ T lymphocytes due to some variation (Fig. 2C). We did
not find any specific anti-epitope antibody in the sera from all
groups of the mice (data not shown). In summary, only peptides 14
and 23 were found capable of activating CD8
+ lymphocytes
triggering proliferation as well as cytokine production.
Efficacy of the CD8 epitope-based vaccine against live
RSV
The immunoprotective ability of the individual CD8 epitopes
derived from RSV F protein against live RSV challenge was
assessed in peptide-immunized HLA-Tg B6 mice. The parameters
selected to assess protection were the measurement of viremia in
the lungs and the recovery from virus-induced body weight loss.
The presence of viremia in the lungs of peptide-immunized
mice challenged with RSV was measured. A more sensitive and
accurate assay, real time RT-PCR specific for RSV N gene as
described in the Materials and Methods was carried out, to
determine the viral load in the lungs. The N gene encodes a
RNAse-resistant nucleocapsid, which binds to genomic and
antigenomic viral RNA in the process of viral particle formation
[41]. Quantification of RSV N gene expression with real time RT-
PCR to score clinical lung viremia has been shown to be a better
Figure 1. Induction of IFN-c and IL-2 in splenocytes from RSV F peptide immunized HLA-A*0201 transgenic mice upon secondary
recall. Splenocytes harvested on day 30 from HLA-A-Tg B6 mice primed and boosted at 20 days interval intranasally with 10
7 pfu of rAd-F0 (%)o r
10
4 pfu of RSV-B1 (&)were restimulated with 2 mg of the individual RSV F peptide or 10 mg/ml Con A for 5 days in the presence of murine IL-2 . After
stimulation, 5610
5 splenocytes were seeded to anti-IFN-c (A) or anti-IL-2 (B) capture antibody coated ELISPOT plates for 2 days for ELISPOT assay as
described in Materials and Methods. Cytokine-positive immunospots were developed and the results are expressed as the number of immunospots
+/22 standard deviations for each experimental group. Data is representative of results derived from two independent experiments, each with five
mice per group.
doi:10.1371/journal.pone.0025500.g001
Novel HLA-A2 CTL Epitopes in RSV F Protein
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25500method than plaque assay [42]. At the peak of virus replication
(day 4 post-infection), a marked reduction in the expression of
RSV N gene (mean=0.51) was observed in mice immunized with
two doses of peptide 23 followed by challenge with 1610
7 pfu of
live RSV-B1 virus, as compared to animals administrated with the
vehicle (mean=0.95). Animals pre-immunized with the peptides
3, 13 or 14 showed no significant reduction of the viral load
(Fig. 3A). Viremia was also noted to be undetectable on day 7 post-
infection in animals immunized with each of these peptides (data
not shown).
Primary RSV infection of adult BALB/c mice has been
observed to cause weight loss in the early stages [11]. We
monitored the body weight of mice immunized with the different
peptides and observed loss of body weight upon RSV challenge in
all the groups. Maximal body weight loss (about 220%) was
observed two days post the viral challenge, following which, the
mice were still unable to recover until day 8. Significant recovery
of body weight loss was observed on day 6 to day 8 in peptide-
immunized mice. Mice immunized with peptides 3, 13, or 23
showed better recovery of body weight (211%, 212%, or 212%,
respectively, on day 6) in the subsequent days compared to vehicle-
immunized mice. Peptide 14 immunized mice recovered only in
the last two days (Fig. 3B). However, the completely recovery of
body weight loss by these CD8 peptide immunization is still
limited.
Proinflammatory cytokines induced by peptide
immunization
Many studies have indicated a direct role for CD8
+ T cells in
mediating vaccine-enhanced disease [26,27,43,44] and the
chemokines CCL11, CCL17, and CCL22 are reported to be
important in the development of RSV vaccine-enhanced pulmo-
nary inflammation [16,45,46]. Lung cytokine profile of HLA-Tg
B6 mice immunized with the different peptide epitopes (3, 13, 14
and 23) was analyzed 5 days after RSV challenge to understand
the effect of cytokines on RSV F-specific CD8
+ T cell response.
Real-time RT-PCR analysis of RNA isolated from the lungs of the
immunized mice was carried out using specific primers to detect
CCL11, CCL17, CCL22, IL-13, IL-17, and IL-18. IL-13 is
reported to be required for eosinophil entry into the lungs during
respiratory syncytial virus vaccine-enhanced disease [47]. Pulmo-
nary levels of CCL11 and CCL22 protein were significantly
reduced in IL-13-deficient mice indicating that IL-13 mediates the
recruitment of eosinophils into the lungs by inducing the
production of Th2 chemokines and eosinophil chemotaxis [47].
IL-17 is a CD4
+ T cell-derived cytokine that has been shown to
Figure 2. Epitope-specific CD4
+ and CD8
+ T-cell activation in peptide-immunized HLA-A*0201 transgenic mice. Splenocytes were
isolated on day 17 from mice immunized twice subcutaneously with the peptides 3, 13, 14, 17, 23, or vehicle at day 0 and day 10. The splenocytes
were labeled with CFSE and cultured in the presence or absence of 10 mg/mL of the respective peptides for 8 days. Proliferation of CD4
+ (A) or CD8
+
(B) lymphocytes in response to the different CD8 epitopes was analyzed by flow cytometry using anti-CD4 or CD8 antibodies conjugated with PE-Cy5.
Results are presented as cell division index (CDI) as described in the Materials and Methods. (C) The splenocytes were stimulated in vitro with or
without the peptides and were stained with anti-CD8 antibody conjugated with FITC, and then fixed and stained for intracellular IFN-c using PE-
conjugated anti-IFN-c antibody. The percentage of CD8
+ IFN-c
+ T cells was calculated. *(p,0.05) and **(p,0.01) indicate they are significantly
different from the unstimulated splenocytes. Data is representative of results derived from three independent experiments.
doi:10.1371/journal.pone.0025500.g002
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infection [48,49].
We found that peptide 23-immunized mice showed significant
upregulation of CCL17 and CCL22 (Fig. 4B and 4C), a marginal
increase in IL-13 (Fig. 4D) but no upregulation of CCL11 or
induction of IL-17 (Fig. 4A and 4E). The other peptides did not
alter the induction of these chemokines. Peptide 13, on the other
hand, decreased the expression of IL-13 in the lungs, compared to
peptide 23 and vehicle (Fig. 4D).
IL-18 is a proinflammatory cytokine produced by macrophages,
neutrophils, and airway epithelial cells that can enhance Th1
response [50], promote NK cell activation, and drive antiviral
immunity in mouse infected with RSV coexpressing IL-18 [51].
We observed an increase in IL-18 expression in mice immunized
with peptide 23 (Fig. 4F).
These results indicate that subcutaneous immunization of HLA-
Tg B6 mice with peptide 23 followed by RSV challenge enhances
the expression of inflammatory chemokines especially CCL17,
CCL22, and anti-viral IL-18 in the lungs.
Induction of pulmonary IFN-c and CD8
+ T cell function
Lung eosinophilia associated with RSV infection is known to
cause bronchiolitis in children [52]. In murine studies, pulmonary
illness and eosinophilia have been associated with immunization
with FI-RSV vaccine as well as RSV G protein-encoding
recombinant vaccinia virus (vacvG) [15,53,54,55]. A study showed
that RSV G protein was not an effector in the pulmonary
eosinophilia and immunopathology induced by FI-RSV [56],
indicating that the mechanism of RSV vaccine-enhanced disease is
still poorly understood. This prompted us to investigate the safety
aspect of the CD8 peptide-based vaccination by examining the
correlation between vaccination and lung inflammation.
Transgenic mice immunized twice with the peptides were
challenged with RSV and the secretion of IFN-c in the lungs was
measured. Four days after viral challenge, decreased IFN-c
secretion was found in mice immunized with the peptides,
compared to vehicle (Fig. 5A). We further investigated whether
the reduced expression of IFN-c in peptide-immunized mice lungs
was due to fewer number of CD8
+ T lymphocytes infiltrated into
the lungs. We found that peptide immunization did not lead to a
profound increase in infiltrated pulmonary CD8
+ T lymphocytes
upon RSV challenge (Fig. 5B); in fact, CD8
+ T cell numbers were
lower when immunized with the peptides 13, 14, or 23, compared
to vehicle immunization. But, the CTLs induced by the peptides
13, 14, and 23 were found to be efficient in target cell lysis when
assessed by in vitro CTL assay using congenic HLA-Tg B6 mouse’s
dendritic cells as targets. The target cells were labeled with CFSE/
7AAD (target) and loaded with the respective peptides and mixed
with effector cells at the effector/target (E:T) ratios of 10:1 and
50:1. Peptide 23 induced highly efficient CTLs with maximum
lysis followed by peptides 14 and 13 (Fig. 5C). These results
confirmed that peptides induced pulmonary CTLs activity but
modulated the number of CD8
+ T cells recruited to the lung.
Pulmonary inflammation in immunized mice upon RSV
challenge
To confirm whether CD8 epitope immunization followed by
RSV infection in HLA-Tg mice can induce eosinophilia, we
sectioned the lung tissues and stained with anti-major basic protein
(MBP), which is a marker of eosinophilia. In the control HLA-Tg
mouse lung, very few eosinophils were present in the lung
mesenchyme (Fig. 6A). Primary RSV infection induced some
clusters of infiltrated eosinophils in the mesenchymal tissues [57],
as seen in the vehicle immunized mice infected with RSV.
Peptides 3, 14, and 23 showed comparable eosinophil numbers in
Figure 3. Determination of lung viral load and gain of lost body weight. Mice were immunized twice intranasally with vehicle (&), peptide 3
(e), peptide 13 (m),peptide 14 (h), or peptide 23 (%) before being intranasally challenged with 10
7 pfu of live RSV B1. (A) The viral load in the lungs
of individual mice was determined 4 days after challenge by real-time RT-PCR to quantitate RSV N gene expression as described in the Materials and
Methods. 10 mice per group were used and the results are expressed as the relative expression of N gene normalized to GAPDH gene expression for
each mouse. *(p,0.05) indicates they are significantly different from the vehicle-immunized group. (B) The body weight of each mouse was recorded
daily for 9 days after virus challenge. Results are expressed as % (mean) for 5 mice in each experimental group. Two independent experiments were
performed and data from one is shown. P value ,0.05 calculated for peptide 3, peptide 13, peptide 14, and peptide 23 indicates they are significantly
different compared to vehicle-immunized control.
doi:10.1371/journal.pone.0025500.g003
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numbers were significantly reduced in the lungs of peptide 13-
immunized mice (Fig. 6B). Indeed, prevention of pulmonary
eosinophilia by peptide 13 also correlates to the lower secretion of
IL-13 (an eosinophil chemotaxisic factor [47]) as shown in Fig. 4D.
In summary, these results implicate the differential activity of
HLA-A*0201-restriced CD8
+ epitopes derived from RSV F. The
peptides not only contribute to viral clearance (peptide 23, F559–
567), but also reduce lung inflammation induced by RSV infection
(peptide 13, F559–567) in HLA-Tg B6 mice.
Discussion
CD8
+ T cell response is crucial for the development of host
adaptive immunity against viral infection. Previous studies
conducted in mice [58,59] and in human [18] showed that the
RSV F protein elicited CTL responses conferred protection
against live RSV infection. The CTL epitopes restricted to the
murine K
d molecules have been identified to comprise of the
amino acids F85–93, F92–106, and F249–258 of the F protein
[24,25,60]. The residues F118–126, F551–559, and F109–118
have been found to be epitopes presented in the context of HLA-
B*57, HLA-Cw*12, and HLA-A*01 alleles [19,61]. Our studies
show that the F protein of RSV is rich in motifs that bind to HLA-
A*0201 molecules. Peptide 13 (F214–222), 14 (F273–281), and 23
(F559–567) presented by HLA-A*0201 as 9-mer, have been
previously identified algorithmically [62], in which the immuno-
genicity of these epitopes was still unclear. The sequence of
peptide 14 (YMLTNSELL) is covered by an identified mouse K
d-
restricted epitope, a 10-mer F249–258 (TYMLTNSELL) peptide
[24,25,60], meant to be a cross-species of CD8 epitope located in
the F protein of RSV.
The algorithmically predicted RSV F-specific CD8
+ epitopes
used in our study are confirmed to bind to human HLA-A*0201 as
well as elicit Th1 cytokine response in HLA Tg mice infected with
RSV or rAd-F0 (Table 1). Two of the synthesized peptides, 14 and
Figure 4. Expression of proinflammatory chemokines in the lungs of HLA-A*0201 transgenic mice immunized with CD8 epitopes
and challenged with RSV. At day 4 post RSV challenge, lung RNA was extracted from the individual mice subcutaneously immunized twice with
IFA-emulsified peptides or vehicle (IFA only). RNA was subjected to quantitative expression analysis of CCL11 (A), CCL17 (B), CCL22 (C), IL-13 (D), IL-17
(E), and IL-18 (F) by real-time RT-PCR using specific primers. GAPDH was used as internal control. The results are representative of the relative
expression of the target gene normalized to GAPDH expression for the individual mouse. *(p,0.05) indicates the treatment is significantly different
from the vehicle-immunized control. Similar results were obtained from two independent experiments, each with six mice per group, and one of
them is shown.
doi:10.1371/journal.pone.0025500.g004
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CD8
+ T cells (Fig. 2) in HLA-Tg mice. A direct correlation was
observed between the magnitude of the CTL responses that were
induced by these peptides and viral clearance. In HLA Tg mice
challenged with live RSV, the maximum CD8
+ activity was
observed in peptide 23 immunizated mice (Fig. 5) along with
enhanced secretion of inflammatory chemokines and NK
activators such as CCL 17, CCL22, and IL-18 in the lungs
(Fig. 4). These factors would have contributed to the observed
enhanced viral clearance. Peptide 14 produced moderately
efficient CTLs and therefore reduced lung viral load only
marginally (Fig. 3A).
Interestingly, peptide 3 and 13 showed significant prevention of
mice weight loss induced by live RSV infection (Fig. 3B) in spite of
reduced activity of the elicited CTLs, as compared to peptide 14 or
23 that elicited stronger CTL activities in mice (Fig. 3C), where
recovery of body weight loss was only mild (Fig. 3B). These results
corroborate a previous report that CD8
+ T cells induced in mice
immunized with vacvF and challenged with live RSV contributed
to body weight loss in the presence of Th1 cytokines [44]. The
exact mechanism of prevention of RSV-induced weight loss by the
peptides 3 and 13 derived from RSV F is still being investigated.
A recent study has generally questioned the role of CTLs in the
pathogenesis of human RSV infection [63]. Very few CD8
+ T cells
were found in the lung infiltrates of human infants infected with
lethal RSV. Additionally, the presence of T cell cytokines in the
nasal secretion was also low and few CTLs were recovered from
BAL of infants with bronchiolitis [63]. A similar phenomenon was
observed in our study; it was noted that in HLA-Tg B6 mice
immunized with IFA (vehicle) and infected with RSV, few
pulmonary CD8
+ T cells were recovered (Fig. 5), and the
expression of inflammatory chemokines was low (Fig. 4). It is
reported that a number of chemokines such as CCL2, CCL5,
CXCL10 are associated with RSV-induced airway hyperrespon-
siveness [64,65] and CCL11, CCL17, and CCL 22 are involved in
the development of pulmonary eosinophilia with RSV infection
[7,16,45,46]. In murine model, development of pulmonary
eosinophilia in BALB/c mice immunized with vacvG followed
Figure 5. Induction of pulmonary IFN-c and CTL activity in peptide immunized transgenic mice challenged with RSV. At day 4 post
RSV infection, lung homogenates were prepared and the following were measured. (A) IFN-c expression by ELISA, and (B) the number of CD8
+ T cells
in the lungs by flow cytometry using PE-cy5-labeled anti-CD8 antibody. (C). Enumeration of CTL activity in the lungs of mice immunized with CD8
peptide epitopes and challenged with RSV. Effector lymphocytes isolated from the lungs of mice immunized with peptide 3 (&), peptide 13 (m),
peptide 14 (.), or peptide 23 (N) were cultured and supplemented with murine IL-2 in the presence of 2 mg of the same peptide for 5 days. In
parallel, cultured pulmonary lymphocytes from vehicle-immunized mice were stimulated with 2 mg of peptide 3 (%), peptide 13 (D), peptide 14 (h),
or peptide 23 (o), respectively, for 4 days. DCs isolated from the tibia of HLA-B6 mice were pulsed with 20 mg per mL of the individual peptides for
2 hours at 37uC and labeled with CFSE and used as targets in the in vitro CTL assay. Un-pulsed DCs served as negative control. The viable effector cells
were co-cultured with 10
4 peptide-loaded target DCs cells at effector:target ratios of 50:1, 10:1, and 0:1 for five hours. The cell mixtures were labeled
with 7-AAD and analyzed by flow cytometry. Results are expressed as mean percentage of 7-AAD/CFSE positive cells normalized with un-pulsed DCs.
Six mice were taken in each group. The result is a representative of two independent experiments.
doi:10.1371/journal.pone.0025500.g005
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vacvG+vacvM2 that increased the number of M282-specific CD8+
T cells and inhibited CCL17 and CCL22 expression in the lungs
[7]. In our study, the cytokine profile of peptide 23-immunized
mice depicting elevated CCL17, CCL22, and IL-18 might have
contributed to the antiviral responses rather than the induction of
lung inflammation, in which no significant eosinophilia was
observed (Fig. 6).
Although a previous report showed that CD4
+ CD25
+ Foxp3
+
Treg cells might be involved in enhancing the migration of virus-
specific CD8 T cells into the lungs [66], we do not observe this
phenomenon in our study. Instead, our unshown results show
increased infiltration of CD4
+CD25
+ T cells in the lungs of mice
pre-immunized with peptides 13, 14, or 23, and challenged with
live RSV. This correlates with the reduced IFN-c level and
reduced infiltration of CD8
+ T cells with normal CTL activity
(Fig. 5).
Significant reduction of eosinophil counts in the lungs of mice
immunized with peptide 13 (Fig. 6) correlates with the reduced
number of infiltrated CD8
+ T cells in the lungs (Fig. 5).
Importantly, we also observed the level of IL-13 associated with
the induction of eosinophilia in FI-RSV or vacvG-immunized
mice challenged with live RSV [47,67] was reduced (Fig. 4).
Compared to vehicle-pre-immunized mice, pre-immunization
with peptides 14 and 23 elicited normal expression of IL-13
(Fig. 4) and there was no enhanced recruitment of eosinophils to
the lungs (Fig. 6). These results not only elucidate that these
peptides derived from RSV F are able to prevent RSV-induced
lung illness (eosinophilia) but also corroborate earlier reports that
co-immunization with vacvF and vacvG individually inhibits
vacvG-enhanced pulmonary eosinophilia upon RSV infection
[14,15,68,69,70]. We believe that our study is the first to
demonstrate RSV F-derived CD8 epitopes in the regulation of
the lung inflammation induced by RSV infection.
Immunization with a single CTL epitope has previously been
shown to induce protection against viral infection or tumor growth
[71,72]. In some cases, protective responses were only induced
following immunization with CTL epitope linked to a T helper
epitope or other carrier [73]. Our unpublished data shows that
HLA-Tg B6 administered with two doses of peptide 23 mixed with
HCV T helper epitope prior to challenge with RSV could not see
the enhancement of antiviral activity in the lungs.
In conclusion, we have identified two distinct HLA-A*0201-
restriced CD8 epitopes, peptide 14 (F273–281) and peptide 23
(F559–567) from RSV F that elicit dominant activation of CD8
+ T
lymphocytes, and are capable of moderate to significant viral
clearance, and also help restoration of body weight loss induced by
RSV infection. Other identified epitopes also elicit different anti-
Figure 6. Eosinophil infiltration into the lungs of peptide-immunized transgenic mice upon RSV challenge. Immunohistochemical
analysis of lung sections with anti-major basic protein antibody specific for eosinophils followed by the HRP-conjugated anti-rat antibody was
performed. (A) Pictures from the section of normal mouse lung (a), or vehicle- (b), peptide 3- (c), 13- (d), 14- (e) and 23- (f) immunized mouse lung
section. (B) Quantitative representation of eosinophil count per section of peptide- or vehicle-immunized HLA-transgenic mice at day 4 post RSV
challenge. Twenty bright field pictures from each lung mesenchymal region were examined and the number of eosinophils was counted under 2006
magnification. The mean number of eosinophils in each group, six mice per group, is represented. Similar results from two independent experiments
were obtained and one of the results is shown.
doi:10.1371/journal.pone.0025500.g006
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capable of limiting body weight loss, and peptide 13 can prevent
RSV-induced lung eosinophilia. These observations would allow
us to further pursue the development of multiple-CD8 epitopes-
based prototype RSV vaccine, which would not contribute to
vaccine-enhanced diseases.
Author Contributions
Conceived and designed the experiments: YHC. Performed the experi-
ments: HYS YWL SLY YCC. Analyzed the data: HYS EC CS PC MTH.
Contributed reagents/materials/analysis tools: PC MTH. Wrote the
paper: YHC OLW EC. Design of experiments and discussion: YHC CS
PC. Made the result of figure 6: HYL.
References
1. Falsey AR (2005) Respiratory syncytial virus infection in elderly and high-risk
adults. Exp Lung Res 31 Suppl 1: 77.
2. Holzel A, Parker L, Patterson WH, White LL, Thompson KM, et al. (1963) The
isolation of respiratory syncytial virus from children with acute respiratory
disease. Lancet 1: 295–298.
3. Chanock RFL (1957) Recovery from infants with respiratory illness of a virus
related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection
in infants and young children. Am J Hyg 66: 291–300.
4. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, et al. (1969)
Respiratory syncytial virus disease in infants despite prior administration of
antigenic inactivated vaccine. Am J Epidemiol 89: 422–434.
5. Graham BS, Bunton LA, Wright PF, Karzon DT (1991) Role of T lymphocyte
subsets in the pathogenesis of primary infection and rechallenge with respiratory
syncytial virus in mice. J Clin Invest 88: 1026–1033.
6. Olson MR, Varga SM (2008) Pulmonary immunity and immunopathology:
lessons from respiratory syncytial virus. Expert Rev Vaccines 7: 1239–1255.
7. Olson MR, Hartwig SM, Varga SM (2008) The number of respiratory syncytial
virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to
inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol 181:
7958–7968.
8. Olson MR, Varga SM (2007) CD8 T cells inhibit respiratory syncytial virus
(RSV) vaccine-enhanced disease. J Immunol 179: 5415–5424.
9. Isaacs D (1991) Viral subunit vaccines. Lancet 337: 1223–1224.
10. Chang J, Choi SY, Jin HT, Sung YC, Braciale TJ (2004) Improved effector
activity and memory CD8 T cell development by IL-2 expression during
experimental respiratory syncytial virus infection. J Immunol 172: 503–508.
11. Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ (2008) The role
of T cells in the enhancement of respiratory syncytial virus infection severity
during adult reinfection of neonatally sensitized mice. J Virol 82: 4115–4124.
12. Aung S, Tang YW, Graham BS (1999) Interleukin-4 diminishes CD8(+)
respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. J Virol
73: 8944–8949.
13. Bukreyev A, Belyakov IM, Prince GA, Yim KC, Harris KK, et al. (2005)
Expression of interleukin-4 by recombinant respiratory syncytial virus is
associated with accelerated inflammation and a nonfunctional cytotoxic T-
lymphocyte response following primary infection but not following challenge
with wild-type virus. J Virol 79: 9515–9526.
14. Srikiatkhachorn A, Braciale TJ (1997) Virus-specific memory and effector T
lymphocytes exhibit different cytokine responses to antigens during experimental
murine respiratory syncytial virus infection. J Virol 71: 678–685.
15. Openshaw PJ, Clarke SL, Record FM (1992) Pulmonary eosinophilic response
to respiratory syncytial virus infection in mice sensitized to the major surface
glycoprotein G. Int Immunol 4: 493–500.
16. Castilow EM, Olson MR, Meyerholz DK, Varga SM (2008) Differential role of
gamma interferon in inhibiting pulmonary eosinophilia and exacerbating
systemic disease in fusion protein-immunized mice undergoing challenge
infection with respiratory syncytial virus. J Virol 82: 2196–2207.
17. Hussell T, Baldwin CJ, O’Garra A, Openshaw PJ (1997) CD8+ T cells control
Th2-driven pathology during pulmonary respiratory syncytial virus infection.
Eur J Immunol 27: 3341–3349.
18. Cherrie AH, Anderson K, Wertz GW, Openshaw PJ (1992) Human cytotoxic T
cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K,
and 1b proteins of respiratory syncytial virus. J Virol 66: 2102–2110.
19. Rock MT, Crowe JE, Jr. (2003) Identification of a novel human leucocyte
antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory
syncytial virus fusion protein. Immunology 108: 474–480.
20. Venter M, Rock M, Puren AJ, Tiemessen CT, Crowe JE, Jr. (2003) Respiratory
syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African
population of diverse HLA types are conserved in circulating field strains. J Virol
77: 7319–7329.
21. Terrosi C, Di Genova G, Savellini GG, Correale P, Blardi P, et al. (2007)
Immunological characterization of respiratory syncytial virus N protein epitopes
recognized by human cytotoxic T lymphocytes. Viral Immunol 20: 399–406.
22. Heidema J, de Bree GJ, De Graaff PM, van Maren WW, Hoogerhout P, et al.
(2004) Human CD8(+) T cell responses against five newly identified respiratory
syncytial virus-derived epitopes. J Gen Virol 85: 2365–2374.
23. Bangham CR, Openshaw PJ, Ball LA, King AM, Wertz GW, et al. (1986)
Human and murine cytotoxic T cells specific to respiratory syncytial virus
recognize the viral nucleoprotein (N), but not the major glycoprotein (G),
expressed by vaccinia virus recombinants. J Immunol 137: 3973–3977.
24. Chang J, Srikiatkhachorn A, Braciale TJ (2001) Visualization and characteriza-
tion of respiratory syncytial virus F-specific CD8(+) T cells during experimental
virus infection. J Immunol 167: 4254–4260.
25. Jiang S, Borthwick NJ, Morrison P, Gao GF, Steward MW (2002) Virus-specific
CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide
from the fusion protein of respiratory syncytial virus. J Gen Virol 83: 429–438.
26. Openshaw PJ, Anderson K, Wertz GW, Askonas BA (1990) The 22,000-
kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted
cytotoxic T lymphocytes from mice primed by infection. J Virol 64: 1683–1689.
27. Rutigliano JA, Rock MT, Johnson AK, Crowe JE, Jr., Graham BS (2005)
Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in
the matrix protein of respiratory syncytial virus. Virology 337: 335–343.
28. Pemberton RM, Cannon MJ, Openshaw PJ, Ball LA, Wertz GW, et al. (1987)
Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein
is an important target antigen. J Gen Virol 68(Pt 8): 2177–2182.
29. Goulder PJ, Lechner F, Klenerman P, McIntosh K, Walker BD (2000)
Characterization of a novel respiratory syncytial virus-specific human cytotoxic
T-lymphocyte epitope. J Virol 74: 7694–7697.
30. Huang YH, Tao MH, Hu CP, Syu WJ, Wu JC (2004) Identification of novel
HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen
Virol 85: 3089–3098.
31. Ding FX, Wang F, Lu YM, Li K, Wang KH, et al. (2009) Multiepitope peptide-
loaded virus-like particles as a vaccine against hepatitis B virus-related
hepatocellular carcinoma. Hepatology.
32. Mott KR, Chentoufi AA, Carpenter D, Benmohamed L, Wechsler S, et al.
(2009) A glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus types
1 and 2 increases ocular virus replication and pathogenicity. Invest Ophthalmol
Vis Sci.
33. Wahl A, Schafer F, Bardet W, Buchli R, Air GM, et al. (2009) HLA class I
molecules consistently present internal influenza epitopes. Proc Natl Acad
Sci U S A 106: 540–545.
34. Krishnan A, Wang Z, Srivastava T, Rawal R, Manchanda P, et al. (2008) A
novel approach to evaluate the immunogenicity of viral antigens of clinical
importance in HLA transgenic murine models. Immunol Lett 120: 108–116.
35. La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, et al. (2002)
Preclinical development of an adjuvant-free peptide vaccine with activity against
CMV pp65 in HLA transgenic mice. Blood 100: 3681–3689.
36. Colleton BA, Huang XL, Melhem NM, Fan Z, Borowski L, et al. (2009) Primary
human immunodeficiency virus type 1-specific CD8+ T-cell responses induced
by myeloid dendritic cells. J Virol 83: 6288–6299.
37. Shao HY, Yu SL, Sia C, Chen Y, Chitra E, et al. (2009) Immunogenic
properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenovi-
ruses. Vaccine.
38. Russell JH, Ley TJ (2002) Lymphocyte-mediated cytotoxicity. Annu Rev
Immunol 20: 323–370.
39. Cannon MJ, Openshaw PJ, Askonas BA (1988) Cytotoxic T cells clear virus but
augment lung pathology in mice infected with respiratory syncytial virus. J Exp
Med 168: 1163–1168.
40. Chiba Y, Higashidate Y, Suga K, Honjo K, Tsutsumi H, et al. (1989)
Development of cell-mediated cytotoxic immunity to respiratory syncytial virus
in human infants following naturally acquired infection. J Med Virol 28:
133–139.
41. Collins PL, Graham BS (2008) Viral and host factors in human respiratory
syncytial virus pathogenesis. J Virol 82: 2040–2055.
42. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM, et al. (2005)
Comparison of a real-time reverse transcriptase PCR assay and a culture
technique for quantitative assessment of viral load in children naturally infected
with respiratory syncytial virus. J Clin Microbiol 43: 2356–2362.
43. Nicholas JA, Rubino KL, Levely ME, Adams EG, Collins PL (1990) Cytolytic T-
lymphocyte responses to respiratory syncytial virus: effector cell phenotype and
target proteins. J Virol 64: 4232–4241.
44. Castilow EM, Varga SM (2008) Overcoming T cell-mediated immunopathology
to achieve safe RSV vaccination. Future Virol 3: 445–454.
45. Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ (2005) Role of
CCL11 in eosinophilic lung disease during respiratory syncytial virus infection.
J Virol 79: 2050–2057.
46. Monick MM, Powers LS, Hassan I, Groskreutz D, Yarovinsky TO, et al. (2007)
Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal
levels of TARC/CCL17. J Immunol 179: 1648–1658.
47. Castilow EM, Meyerholz DK, Varga SM (2008) IL-13 is required for eosinophil
entry into the lung during respiratory syncytial virus vaccine-enhanced disease.
J Immunol 180: 2376–2384.
48. Hashimoto K, Durbin JE, Zhou W, Collins RD, Ho SB, et al. (2005) Respiratory
syncytial virus infection in the absence of STAT 1 results in airway dysfunction,
airway mucus, and augmented IL-17 levels. J Allergy Clin Immunol 116:
550–557.
Novel HLA-A2 CTL Epitopes in RSV F Protein
PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e2550049. Peebles RS, Jr., Graham BS (2005) Pathogenesis of respiratory syncytial virus
infection in the murine model. Proc Am Thorac Soc 2: 110–115.
50. Xu D, Chan WL, Leung BP, Huang F, Wheeler R, et al. (1998) Selective
expression of a stable cell surface molecule on type 2 but not type 1 helper T
cells. J Exp Med 187: 787–794.
51. Harker JA, Godlee A, Wahlsten JL, Lee DC, Thorne LG, et al. (2010)
Interleukin 18 coexpression during respiratory syncytial virus infection results in
enhanced disease mediated by natural killer cells. J Virol 84: 4073–4082.
52. Ehlenfield DR, Cameron K, Welliver RC (2000) Eosinophilia at the time of
respiratory syncytial virus bronchiolitis predicts childhood reactive airway
disease. Pediatrics 105: 79–83.
53. Doherty PC (1994) Vaccines and cytokine-mediated pathology in RSV infection.
Trends Microbiol 2: 148–149; discussion 149–150.
54. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ (1996) Respiratory
synctial virus infection in BALB/c mice previously immunized with formalin-
inactivated virus induces enhanced pulmonary inflammatory response with a
predominant Th2-like cytokine pattern. J Virol 70: 2852–2860.
55. Graham BS, Rutigliano JA, Johnson TR (2002) Respiratory syncytial virus
immunobiology and pathogenesis. Virology 297: 1–7.
56. Johnson TR, Teng MN, Collins PL, Graham BS (2004) Respiratory syncytial
virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease
induced by immunization with formalin-inactivated RSV. J Virol 78:
6024–6032.
57. Kruijsen D, Schijf MA, Lukens MV, van Uden NO, Kimpen JL, et al. (2011)
Local innate and adaptive immune responses regulate inflammatory cell influx
into the lungs after vaccination with formalin inactivated RSV. Vaccine 29:
2730–2741.
58. Alwan WH, Record FM, Openshaw PJ (1993) Phenotypic and functional
characterization of T cell lines specific for individual respiratory syncytial virus
proteins. J Immunol 150: 5211–5218.
59. Kulkarni AB, Connors M, Firestone CY, Morse HC, 3rd, Murphy BR (1993)
The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection
with a vaccinia virus recombinant expressing the M2 protein of respiratory
syncytial virus (RSV), correlates with resistance to RSV infection in mice. J Virol
67: 1044–1049.
60. Johnstone C, de Leon P, Medina F, Melero JA, Garcia-Barreno B, et al. (2004)
Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in
the F glycoprotein of the Long strain of respiratory syncytial virus. J Gen Virol
85: 3229–3238.
61. Brandenburg AH, de Waal L, Timmerman HH, Hoogerhout P, de Swart RL,
et al. (2000) HLA class I-restricted cytotoxic T-cell epitopes of the respiratory
syncytial virus fusion protein. J Virol 74: 10240–10244.
62. Agenbach E, Tiemessen CT, Venter M (2005) Amino acid variation within the
fusion protein of respiratory syncytial virus subtype A and B strains during
annual epidemics in South Africa. Virus Genes 30: 267–278.
63. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, et al. (2007)
Severe human lower respiratory tract illness caused by respiratory syncytial virus
and influenza virus is characterized by the absence of pulmonary cytotoxic
lymphocyte responses. J Infect Dis 195: 1126–1136.
64. Miller AL, Bowlin TL, Lukacs NW (2004) Respiratory syncytial virus-induced
chemokine production: linking viral replication to chemokine production in vitro
and in vivo. J Infect Dis 189: 1419–1430.
65. Tekkanat KK, Maassab H, Miller A, Berlin AA, Kunkel SL, et al. (2002)
RANTES (CCL5) production during primary respiratory syncytial virus
infection exacerbates airway disease. Eur J Immunol 32: 3276–3284.
66. Fulton RB, Meyerholz DK, Varga SM (2010) Foxp3+ CD4 regulatory T cells
limit pulmonary immunopathology by modulating the CD8 T cell response
during respiratory syncytial virus infection. J Immunol 185: 2382–2392.
67. Johnson TR, Parker RA, Johnson JE, Graham BS (2003) IL-13 is sufficient for
respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory
syncytial virus challenge. J Immunol 170: 2037–2045.
68. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, et al. (1998)
Priming with secreted glycoprotein G of respiratory syncytial virus (RSV)
augments interleukin-5 production and tissue eosinophilia after RSV challenge.
J Virol 72: 2871–2880.
69. Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, et al. (1998) Host
genetic determinants of vaccine-induced eosinophilia during respiratory
syncytial virus infection. J Immunol 161: 6215–6222.
70. Hancock GE, Tebbey PW, Scheuer CA, Pryharski KS, Heers KM, et al. (2003)
Immune responses to the nonglycosylated ectodomain of respiratory syncytial
virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains
of mice with different MHC haplotypes. J Med Virol 70: 301–308.
71. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, et al.
(1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide
protects against a tumor induced by human papillomavirus type 16-transformed
cells. Eur J Immunol 23: 2242–2249.
72. Blaney JE, Jr., Nobusawa E, Brehm MA, Bonneau RH, Mylin LM, et al. (1998)
Immunization with a single major histocompatibility complex class I-restricted
cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2
confers protective immunity. J Virol 72: 9567–9574.
73. Partidos CD, Vohra P, Steward MW (1996) Induction of measles virus-specific
cytotoxic T-cell responses after intranasal immunization with synthetic peptides.
Immunology 87: 179–185.
Novel HLA-A2 CTL Epitopes in RSV F Protein
PLoS ONE | www.plosone.org 13 September 2011 | Volume 6 | Issue 9 | e25500